ClinicalTrials.gg
RecruitingNCT04751331Updated Apr 21, 2026

Neural Response to Inflammatory Challenge in Major Depressive Disorder

A Phase 1/2 interventional study of LPS and Saline in Major Depressive Disorder, sponsored by Laureate Institute for Brain Research, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Laureate Institute for Brain Research, Inc. · Phase 1/2, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Depressive Disorder, Major by Laureate Institute for Brain Research, Inc. — 1 open to participants now, 2 under way, none of them phase 3. Depressive Disorder, Major · Laureate Institute for Brain Research, Inc..

Planned enrollment
Largest of 11
180 · median 54
Started
2021
with 1 other
Phase 1/2
2 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Depressive Disorder, Major by Laureate Institute for Brain Research, Inc., this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1/2, and was the 9th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 12 studies in Depressive Disorder, Major by Laureate Institute for Brain Research, Inc. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Depressive Disorder, Major by Laureate Institute for Brain Research, Inc., or all of them as a file.
02

Study summary

This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30).

There are three main aims: to identify immune pathways and neural circuits that respond differently to LPS in MDD vs. HC subjects; (2) to test whether the strength of inflammatory changes induced by LPS is associated with degree of change in anhedonic symptoms and neural circuits in the MDD group, and (3) to identify a biotype of MDD that shows a differential immunological and neurophysiological response to LPS. The main outcome variables are symptoms of anhedonia measured with the Snaith-Hamilton Pleasure Scale (SHAPS), cytokines (Il-6, IL-8, IL-10, and TNF), and BOLD signal change in the neural circuitry mediating interoceptive processing, i.e. the insula and cingulate cortex. The exploratory aim is to determine whether the acute inflammatory response to LPS can predict the clinical course of depression over a period of six months. The main outcome of this component of the study is self-reported depressive symptoms assessed with the QIDS-SR.

Read the detailed description

This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30). Individuals who are eligible for the study will be randomly assigned through the use of a block randomization scheme to ensure the inclusion of equal numbers of HC and MDD participants in each group. MDD participants will complete up to 10 study visits (V1-V10) while the HCs will complete up to four visits (V1-V4). At visit 1 (V1), each subject will be consented and will complete the following: self-report and clinician-administered scales (including the Columbia Suicide Severity Rating Scale), a physical exam that includes an EKG and vital signs (temperature, pulse, blood pressure), safety labs (CBC, CMP, TSH, HbA1C, HIV, HCV), a urine drug screen, an alcohol breathalyzer, and a baselineMRI session comprising the following scans: clinical, anatomical, visceral interoceptive attention (VIA) task, monetary incentive delay task (MID) and resting state fMRI. Vital signs will be assessed in a supine position with a completely automated device. Blood pressure and heart-rate measurements will be preceded by at least five minutes of rest in a quiet setting without distractions. Blood will be drawn via venipuncture using sterile techniques by a trained phlebotomist or nurse.

Subjects that pass the safety screen return two days later for the experimental session (V2). Prior to infusion of LPS or saline, the Columbia, EKG, urine drug screen, and breathalyzer are repeated, vital signs are taken, and baseline (T0) rating scales and blood draws are completed. A nurse will insert a catheter with a heparin lock into the non-dominant forearm for blood draws and a continuous saline flush, and one into the dominant forearm for LPS or saline administration. Prior to the LPS/saline infusion, participants will be hydrated with 500cc of saline. The LPS to be used in the study will be obtained from the NIH Clinical Center. Vital signs will be assessed every 30 min post infusion of LPS/saline for the first 2 hours (and thereafter every hour). Blood samples will be taken at baseline (T0), at T1 and then at T1.5 and T3.5 (\~ peak response) and prior to discharge at T6. Participants also will complete hourly measures of sickness symptoms (e.g., fatigue, pain), anxiety, depression, and anhedonia. Symptoms will be recorded and graded according to FDA criteria. Two hours post-infusion at the approximate peak of the inflammatory response, the participants will complete the same MRI scans as at baseline. Subject to the judgment of a physician, the participants will be discharged 6 hours post injection so that the total experimental procedure will take \~8 hours to complete. Participants return the following day (T24) and one week later (V4) for mood ratings, blood draws, and identical MRI sessions. MDD participants will also be followed longitudinally for 6 months (phase 2), in the process completing remote or in-person psychological assessments at months 1 through 6 post LPS-infusion.

Participants will be recruited from the Tulsa metropolitan area through internet, radio, print advertisements and will be evaluated at LIBR. We may also advertise the study to students on Tulsa-area campuses using flyers and potentially also recruitment tables on campus, and discussions with organizations, classes, and faculty where permission from the appropriate university officials is obtained. A total of 200 human participants (180 completers of phase I) will be involved in the proposed research. Half the participants will be males or females between the ages of 18 and 65 with MDD and current symptoms of depression (mild to severe) and half the participants will be HC with no personal history of psychiatric illness. A DSM-V diagnosis of MDD will be made with the MINI International Neuropsychiatric Interview and current symptoms of depression will be measured with the clinician-administered Montgomery Asberg Depression Rating Scale (MADRS), the self-report Patient Health Questionnaire (PHQ-9), and the Quick Inventory of Depressive Symptoms (QIDS-SR). Depressed participants will be required to be in good general health (as evaluated during the screening visit, including physical exam, safety labs and EKG) and to be 18-65 years of age. MDD participants will be required to have symptoms of depression, that is, a MADRS score of ≥7 or a PHQ-9 score ≥10. MDD participants are also required to be unmedicated for at least 4 weeks (8 weeks for fluoxetine) or currently receiving treatment with only one anti-depressant medication. HC participants will be required to be in good general health and to be 18-65 years of age.

There are three main aims: to identify immune pathways and neural circuits that respond differently to LPS in MDD vs. HC subjects; (2) to test whether the strength of inflammatory changes induced by LPS is associated with degree of change in anhedonic symptoms and neural circuits in the MDD group, and (3) to identify a biotype of MDD that shows a differential immunological and neurophysiological response to LPS. The main outcome variables are symptoms of anhedonia measured with the Snaith-Hamilton Pleasure Scale (SHAPS), cytokines (Il-6, IL-8, IL-10, and TNF), and BOLD signal change in the neural circuitry mediating interoceptive processing (the insula and cingulate cortex), and BOLD signal change in the neural circuitry mediating reward (ventral striatum). The exploratory aim is to determine whether the acute inflammatory response to LPS can predict the clinical course of depression over a period of six months. The main outcome of this component of the study is self-reported depressive symptoms assessed with the QIDS-SR.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both healthy controls and depressed participants will be required to be in good general health (as evaluated during Visit 1, including ) and to be 18-65 years of age. A diagnosis of MDD will be made with the MINI International Neuropsychiatric Interview and current symptoms of depression will be measured with the clinician-administered MADRS and the self-report PHQ-9. Depressed participants will be required to have symptoms of depression (i.e. a PHQ-9 score ≥10) and/or a MADRS score of ≥7.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  • Pregnancy
  • A history of fainting during blood draws will be evaluated by the clinical team and may be deemed exclusionary.

Medical Conditions:

  • Moderate to severe traumatic brain injury (>30 min. loss of consciousness or >24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits.
  • Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders.
  • Presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other disorders.
  • Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk.
  • Presence of chronic infection that may elevate pro-inflammatory cytokines.
  • Presence of an acute infectious illness or receipt of a vaccination in the two weeks prior to an experimental session.

Psychiatric Disorders:

  • Current severe suicidal ideation or attempt within the past 12 months.
  • Psychosis
  • Bipolar disorder
  • Substance abuse or dependence within the previous 6 months

for MRI:

  • Cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy.
  • Claustrophobia that is severe enough to preclude MRI scanning.

Medications:

  • Current and/or past regular use of hormone-containing medications (excluding )
  • Use of medications such as oral which may have effects.
  • Current use of non-steroid anti-inflammatory drugs that is deemed by the investigators to potentially confound the results of the study (e.g. > 3 days/week)
  • Current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists
  • Current use of analgesics such as opioids or history of addiction to opioids or other analgesics
  • Current and/or past regular use of cardiovascular medications, including antihypertensive, antiarrhythmic, anti-anginal, and anticoagulant drugs (does not apply where medications are taken for different purpose e.g. anti-hypertensives for migraine).
  • Chronic use of antibiotics such as isotretinoin or minocycline because of their potential effects on the microbiome and immune function.
  • Evidence of recreational drug use from urine test.
  • Lifetime use of methamphetamine
  • Inclusion of individuals reporting other types of medications or supplements not listed or considered thus far will be at the discretion of the PI based on their potential to affect immune function, the microbiome, brain function or brain blood flow.

Health Factors:

  • > 35 because of the effects of obesity on pro-inflammatory cytokine activity
  • abnormalities on screening laboratory tests
  • Abnormal
  • In addition, participants who on arrival to the study, show any of the following symptoms will not be allowed to complete the study:

    1. screening supine systolic blood pressure >140 mmHg or \<100 mmHg
    2. screening supine diastolic blood pressure >90 mmHg or \<60 mmHg
    3. 12-lead EKG demonstrating a PR interval > 0.2 msec >450 or QRS >120 msec (Bazett) If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the EKG will be repeated 2 more times and the median value will be used
    4. pulse less than 50 beats/minute or greater than 100 beats/minute
    5. temperature greater than 99.5 degrees F.

      Non-English speaking participants:

  • The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    LPS

    Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113) administered as an intravenous bolus.

    Biological: LPS

  • Placebo comparator
    Placebo

    Placebo (same volume of 0.9% saline) administered as an intravenous bolus

    Biological: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. Inflammatory response

    Serum interleukin 6 (IL-6) (pg/mL)

    Time frame: 1.5 hours post infusion

Secondary outcomes

  1. Symptoms of anhedonia

    Snaith-Hamilton Pleasure Scale Score (score range 14-56; higher scores more anhedonia)

    Time frame: 1.5 hours post infusion

  2. Depressive Symptoms

    Change in Depressive Symptoms measures with the Montgomery-Asberg Depression Rating Scale (MADRS). Score range 0-60. Higher scores = more depression.

    Time frame: 24 hours post infusion

  3. Neural response to anticipation of monetary reward

    BOLD Signal Change in the ventral striatum measured using MRI

    Time frame: Two hours post-infusion

  4. Neural response to interoceptive vs exteroceptive stimuli (interoceptive awareness task)

    BOLD Signal Change in the Insula and Posterior Cingulate Cortex measured using MRI

    Time frame: Two hours post infusion

Other outcomes

  1. Temperature

    Body temperature

    Time frame: 3-5 hours post infusion

  2. Inflammatory response

    Serum tumor necrosis factor (TNF) (pg/mL)

    Time frame: 1.5 hours post-infusion

  3. Course of Illness

    Depressive symptoms at 6 month follow-up measured with the Quick Inventory of Depressive Symptoms (QIDS). Score range 0-27. Higher scores = greater depression.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Apr 2026, 59 months after the start.

Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
May 15, 2021
Primary completionEst.
Apr 2026
CompletionEst.
Dec 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04751331
Lead sponsor
Laureate Institute for Brain Research, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
May 15, 2021
Primary completion
Apr 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Jonathan Savitz, PhD
Contact
jsavitz@laureateinstitute.org
918 502 5104

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lipopolysaccharides

Start the discussion